Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MRE11A mutation
i
Other names:
MRE11A, ATLD, MRE11, MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4361
Related biomarkers:
Expression
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/23/2024
Initiation :
07/06/2023
Primary completion :
05/31/2024
Completion :
05/31/2024
BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
|
BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BARD1 mutation • BLM mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • RAD51 mutation
Niraparib in Tumors Metastatic to the CNS (NCT04992013)
Phase 2
Massachusetts General Hospital
Massachusetts General Hospital
Recruiting
Phase 2
Massachusetts General Hospital
Recruiting
Last update posted :
03/11/2024
Initiation :
04/05/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
|
BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • BAP1 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BARD1 mutation • MRE11A mutation • RAD54L mutation • NBN mutation • HRD signature
|
Zejula (niraparib)
Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer (HRPCa-II) (NCT05333432)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Phase N/A
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Last update posted :
02/28/2024
Initiation :
06/01/2024
Primary completion :
07/01/2029
Completion :
07/01/2029
TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13
|
BRCA1 mutation • PTEN mutation • PALB2 mutation • BRIP1 mutation • MSH2 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • BARD1 mutation • BLM mutation • MRE11A mutation • MLH3 mutation • NBN mutation
Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2) (NCT04939662)
Phase 2
Se-Hoon Lee
Se-Hoon Lee
Completed
Phase 2
Se-Hoon Lee
Completed
Last update posted :
01/01/2024
Initiation :
06/11/2021
Primary completion :
10/27/2023
Completion :
10/27/2023
BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
|
BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • BRCA mutation • MRE11A mutation • RAD54L mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib)
M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
Phase 2
Massachusetts General Hospital
Massachusetts General Hospital
Completed
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
07/07/2023
Initiation :
01/08/2019
Primary completion :
06/01/2020
Completion :
07/08/2020
BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC
|
BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
|
berzosertib (M6620)
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE) (NCT04508803)
Phase 2
Fudan University
Fudan University
Recruiting
Phase 2
Fudan University
Recruiting
Last update posted :
06/30/2022
Initiation :
09/14/2020
Primary completion :
11/20/2022
Completion :
12/28/2022
HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression
|
Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B) (NCT03009682)
Phase 2
Samsung Medical Center
Samsung Medical Center
Completed
Phase 2
Samsung Medical Center
Completed
Last update posted :
02/18/2021
Initiation :
08/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
|
BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
|
Lynparza (olaparib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login